Selecting Atezolizumab Plus Bevacizumab Versus Ipilimumab Plus Nivolumab in RCC
Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses how data should be looked at between 2 combinations for the treatment of renal cell carcinoma. He says atezolizumab plus bevacizumab will never be compared head to head with ipilimumab plus nivolumab.
Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses how data should be looked at between 2 combinations for the treatment of renal cell carcinoma (RCC). He says atezolizumab (Tecentriq) plus bevacizumab (Avastin) will never be compared head to head with ipilimumab (Yervoy) plus nivolumab (Opdivo).
Having these 2 combinations is great from a clinician standpoint as they are additional options for patients with RCC. One combination could be more tolerable and suitable for some patients than the other combination, Rini says. It is the clinician’s job to then figure out which combination is best.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
